Oncology

Rethinking cancer treatment with next-generation therapeutics

The global burden of cancer

Cancer remains one of the leading causes of morbidity and mortality worldwide. It arises from the accumulation of genetic and epigenetic alterations that disrupt normal cellular regulation, enabling uncontrolled proliferation, immune evasion, angiogenesis, and metastasis. Despite major advances in surgery, chemotherapy, radiotherapy, and targeted therapies, many malignancies remain difficult to treat, particularly in advanced or resistant stages.

Beyond its biological complexity, cancer presents profound clinical challenges. Tumor heterogeneity, adaptive resistance mechanisms, and immunosuppressive microenvironments often limit the durability of current treatments. These realities drive the urgent need for more precise, adaptable, and personalized therapeutic strategies.

A shift in therapeutic strategy

Traditional cancer treatments largely focus on destroying rapidly dividing cells or inhibiting dysregulated signaling pathways. While often effective, these approaches can lack specificity and cause significant systemic toxicity.

Modern oncology is increasingly shifting toward molecular precision — targeting the specific genetic drivers, signaling networks, and immune interactions that sustain tumor growth. Nucleic acid–based therapeutics now offer the ability to silence oncogenes, restore tumor suppressor function, express therapeutic proteins, reprogram immune cells, and modulate the tumor microenvironment. This transition marks a paradigm shift from broadly attacking tumors to rationally engineering therapeutic responses.

How do nanoparticle technologies enable precision oncology?

Overcoming biological delivery barriers

Nucleic acids face significant physiological barriers, including enzymatic degradation, rapid clearance, and poor cellular uptake. Nanoparticle platforms are engineered to overcome these obstacles, protecting cargo while facilitating targeted intracellular delivery.

Both viral and non-viral systems have been explored in oncology. While viral vectors offer high transduction efficiency, they present challenges including immunogenicity, insertional mutagenesis risks, and complex manufacturing. In contrast, non-viral nanoparticles (e.g., lipid- or polymer-based nanoparticles) provide tunable, modular platforms with improved safety profiles and scalable production potential.

Where are nanoparticle platforms applied in cancer therapy?

Key therapeutic applications

• Cancer immunotherapy – Nanoparticle delivery of mRNA encoding tumor antigens or immunostimulatory factors supports personalized cancer vaccines and in situ immune activation.
• Gene silencing in tumors – Lipid and polymer-based nanoparticles can deliver siRNA, miRNA, or ASOs to suppress oncogenes, angiogenic factors, or drug-resistance pathways.
• Immune cell engineering – Non-viral nanoparticle systems enable ex vivo and in vivo reprogramming of T cells or NK cells, accelerating the development of advanced CAR-T and CAR-NK therapies.
• Tumor microenvironment modulation – Nanocarriers can deliver nucleic acids that reprogram immune cells (e.g., tumor-associated macrophages (TAMs)) within the tumor microenvironment, improving responsiveness to immunotherapy.
• Combination therapies – Nanoparticles allow co-delivery of nucleic acids with chemotherapeutics or immune modulators, enabling synergistic treatment strategies.